Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance

Adaptive Biotechnologies CorpTrade
Invesco S&P 500 Low Volatility ETFTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Invesco S&P 500 Low Volatility ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.98 (market cap $4.05B), while Invesco S&P 500 Low Volatility ETF trades at $75.6. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.

ADPTSPLV
Market Cap
$4.05B
Sector
Health
52-Week High
$25.45$77.97
52-Week Low
$12.15$70.30
Enterprise Value
$4.12B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

Invesco S&P 500 Low Volatility ETF

SPLV trades at $76.21, down 0.07% with neutral technical signals. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty. Recent news highlights its role in diversification as investors seek shelter from tech sell-offs and geopolitical tensions. Moving averages show a bullish trend, while oscillators indicate neutrality, with RSI at 55.45 suggesting balanced momentum.

Outlook: SPLV provides defensive exposure with historical resilience, but reliance on low-volatility factors may lag in bullish markets. Risks include concentrated sector bets and interest rate sensitivity. Analyst sentiment is mixed, reflecting its niche role in risk-averse portfolios.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Invesco S&P 500 Low Volatility ETF

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.

Read more on SPLV